A Trial of HRS-6213 in Healthy Subjects and Patients With Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 10, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

March 31, 2026

Conditions

Patients With Solid Tumors

Interventions

DRUG

HRS-6213

HRS-6213 IV administered as imaging agent for PET scan.

Trial Locations (1)

RECRUITING

Tianjin Medical University Cancer Institute and Hospital, Tianjin

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY